Vaccine, 2016-08, Vol.34 (38), p.4536-4542
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children
- Ist Teil von
- Vaccine, 2016-08, Vol.34 (38), p.4536-4542
- Ort / Verlag
- Netherlands: Elsevier Ltd
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • The GMZ2 fusion protein consist of the non-repeat region of falciparum GLURP genetically fused to a msp3 fragment. • The GMZ2 fusion protein elicited functional antibodies in phase 1 studies. • In the ATP analysis, vaccine efficacy adjusted for age and site was 14% (95% CI: 3.6%, 23%). • Vaccine efficacy was higher in older children. • In GMZ2-vaccinated children, the incidence of malaria decreased with increasing vaccine-induced anti-GMZ2 IgG concentration.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0264-410XeISSN: 1873-2518DOI: 10.1016/j.vaccine.2016.07.041Titel-ID: cdi_proquest_miscellaneous_1815699569
- Format
- –
- Schlagworte
- Adjuvants, Immunologic - administration & dosage, Age, Allergy and Immunology, Aluminum Hydroxide - administration & dosage, Antibodies, Protozoan - blood, Antibody, Antigens, Antigens, Protozoan - immunology, Blood, Burkina Faso, Child, Preschool, Children & youth, Clinical trials, Efficacy, Female, Fever, Gabon, Ghana, GLURP, GMZ2, Humans, Immunoglobulin G - blood, Immunoglobulins, Infant, Malaria, Malaria Vaccines - immunology, Malaria, Falciparum - prevention & control, Male, MSP3, Parasites, Phase 2 clinical trial, Plasmodium falciparum, Proteins, Protozoan Proteins - immunology, Recombinant Fusion Proteins - immunology, Tropical diseases, Uganda, Vaccine, Vaccines